SLN
Price:
$18.31
Market Cap:
$645.03M
Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development of novel ribonucleic acid (RNA) therapeutics in hematology, cardiovascular, and other rare and metabolic indications. The company's platform includes mRNAi GalNAc Oligonucleotide Discovery platform designed to accurately target specific disease-associated genes in the liver. It designs short interfering RNA molecules to harness the body's natural mechanism of RNA interference, and degrading messenger RNA molecules that encode specific targeted disease-associated proteins in a cell. The company is developing various product candidates, including SLN360, which is Phase I clinical trials for the treatmen...[Read more]
Industry
Biotechnology
IPO Date
2020-09-08
Stock Exchange
NASDAQ
Ticker
SLN
According to Silence Therapeutics plc’s latest financial reports and current stock price. The company's current Enterprise Value is 535.74M. This represents a change of 9.93% compared to the average of 487.35M of the last 4 quarters.
The mean historical Enterprise Value of Silence Therapeutics plc over the last ten years is 340.41M. The current 535.74M Enterprise Value has changed 15.64% with respect to the historical average. Over the past ten years (40 quarters), SLN's Enterprise Value was at its highest in in the March 2024 quarter at 647.18M. The Enterprise Value was at its lowest in in the September 2020 quarter at 0.
Average
340.41M
Median
344.14M
Minimum
193.47M
Maximum
452.85M
Discovering the peaks and valleys of Silence Therapeutics plc Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 42.52%
Maximum Annual Enterprise Value = 452.85M
Minimum Annual Increase = -21.88%
Minimum Annual Enterprise Value = 193.47M
Year | Enterprise Value | Change |
---|---|---|
2023 | 452.85M | 28.83% |
2022 | 351.51M | -21.88% |
2021 | 449.95M | 9.27% |
2020 | 411.79M | 16.00% |
2019 | 355.00M | 5.41% |
2018 | 336.77M | 14.64% |
2017 | 293.77M | -10.58% |
2016 | 328.52M | 42.52% |
2015 | 230.50M | 19.14% |
2014 | 193.47M | 23.57% |
The current Enterprise Value of Silence Therapeutics plc (SLN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
418.10M
5-year avg
404.22M
10-year avg
340.41M
Silence Therapeutics plc’s Enterprise Value is greater than Cidara Therapeutics, Inc. (-77580827.00), less than Applied Therapeutics, Inc. (796.79M), greater than CytomX Therapeutics, Inc. (59.90M), less than Shattuck Labs, Inc. (0), greater than C4 Therapeutics, Inc. (119.72M), greater than Eliem Therapeutics, Inc. (450.85M), greater than Prelude Therapeutics Incorporated (332.22M), greater than Monte Rosa Therapeutics, Inc. (130.69M), greater than Opthea Limited (319.09M), less than Centessa Pharmaceuticals plc (622.16M), less than Nuvalent, Inc. (1.75B), less than Tarsus Pharmaceuticals, Inc. (7.13B), less than Genfit S.A. (1.21B), greater than Avidity Biosciences, Inc. (179.29M), less than IGM Biosciences, Inc. (4.78B), less than Cerevel Therapeutics Holdings, Inc. (994.17M), less than Cullinan Oncology, Inc. (8.24B), less than Mineralys Therapeutics, Inc. (927.81M), greater than null (533.84M),
Company | Enterprise Value | Market cap |
---|---|---|
-77580827.00 | $82.49M | |
796.79M | $918.77M | |
59.90M | $91.40M | |
0 | $176.59M | |
119.72M | $455.55M | |
450.85M | $555.26M | |
332.22M | $140.31M | |
130.69M | $383.58M | |
319.09M | $594.00M | |
622.16M | $1.79B | |
1.75B | $7.21B | |
7.13B | $1.32B | |
1.21B | $208.63M | |
179.29M | $5.35B | |
4.78B | $1.02B | |
994.17M | $8.19B | |
8.24B | $1.04B | |
927.81M | $601.69M | |
533.84M | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Silence Therapeutics plc using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Silence Therapeutics plc or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Silence Therapeutics plc's Enterprise Value?
What is the highest Enterprise Value for Silence Therapeutics plc (SLN)?
What is the 3-year average Enterprise Value for Silence Therapeutics plc (SLN)?
What is the 5-year average Enterprise Value for Silence Therapeutics plc (SLN)?
How does the current Enterprise Value for Silence Therapeutics plc (SLN) compare to its historical average?